David S. Riley Materia Medica of New and Old Homeopathic Medicinces David S. Riley Materia Medica of New and Old Homeopathic Medicines 123 David S. Riley MD 6 Amigos Lane Santa Fe, NM 87508 USA ISBN-13 978-3-642-25291-4 Springer-Verlag Berlin Heidelberg New York Bibliographic information Deutsche Bibliothek The Deutsche Bibliothek lists this publication in Deutsche Nationalbibliographie; detailed bibliographic data is available in the internet at <http://dnb.ddb.de>. This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable to prosecution under the German Copyright Law. SpringerMedizin Springer-Verlag GmbH ein Unternehmen von Springer Science+Business springer.de © Springer-Verlag Berlin Heidelberg 2012 The use of general descriptive names, registered names, trademarks, etc. in this publications does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature. Planning: Diana Kraplow Project management: Dr. Astrid Horlacher Copy-Editing: Mary Schäfer, Buchen-Hettingen Cover design: deblik Berlin Typesetting: Fotosatz-Service Köhler GmbH – Reinhold Schöberl, Würzburg 18/5141 – 5 4 3 2 1 0 SPIN 86007571 V Table of Contents Homeopathic Drug Provings – An Introduction to General Methodological Considerations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Acidum cis aconiticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 Acidum citricum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Acidum ketoglutaricum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 Acidum oroticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Acidum succinicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Adenosine monohydrogen phosphate 3’5’ (AMP) . . . . . . . . . . . . . . . . . 19 Adenosine triphosphate (ATP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23 Agnus castus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Anthrachinon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Arteria suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Ascophyllum nodosum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Bacterium coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Barium oxalsuccinicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 Bryonia alba . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 Bryonia dioica . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 Calendula officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 Cardiospermum halicacabum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 Cartilago suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59 Caulophyllum thalictroides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 Citrullus colocynthis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 Coenzyme A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69 VI Table of Contents Cuprum formicium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 Embryo suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73 Fucus vesiculosus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Fumaria officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 Funiculus umbilicalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83 Galphimia glauca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87 Geranium robertianum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 Glandula suprarenalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93 Glyoxal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97 Hepar suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 Human Growth Hormone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 Hydrochinon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105 Insulin-like Growth Factor-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107 Kalium tetraiodobismutate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109 L-Cysteine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 Luffa operculata . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115 Mahonia aquifolium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 Medulla ossis suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123 Methylglyoxal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125 Mucosa nasalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 Myosotis arvensis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 Naphthochinon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131 Natrium oxalaceticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133 Natrium pyruvicum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137 Nicotinamide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 139 VII Table of Contents Nicotinamide adenine dinucleotide (NAD) . . . . . . . . . . . . . . . . . . . . . . 143 Okoubaka aubrevillei . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 145 Oleander . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 Oleum Pini . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149 Oxalis acetosella . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 151 Pancreas suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 Placenta suis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 Potentilla erecta . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163 Pyridoxinum hydrochloricum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167 Riboflavinum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171 Sinusitisinum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 175 Staphylococcus nosode . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179 Streptococcus nosode . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181 Symphytum officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 Terebinthina laricina . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189 Thiamini hydrochloricum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191 Thioctic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195 Trichinoyl . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197 Urtica urens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 Veronica officinalis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203 Zincum aceticum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207 Zinc gluconate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 214 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 215 1 1 Homeopathic Drug Provings – An Introduction to General Methodological Considerations Homeopathic drug provings are one of the pillars of homeopathic knowledge and prescribing and guide homeopathic physicians in their selection of remedies. The primary goal of these provings is to provide accessible information that will help homeopathic physicians improve their practice. As practitioners use these remedies they can then further verify and clarify the symptom picture of the remedy, which will lead to refinement in the repertory. A secondary goal of publishing these provings is to explore proving design and methodology. Homeopathic drug provings dating back to the time of Hahnemann have used homeo- pathically prepared substances administered to healthy subjects who are then observed for the symptoms they experience. Dr. Samuel Hahnemann was a physician, pharmacist, and translator of scientific literature. In 1790 he translated the »Treatise on Materia Medica« by William Cul- len from English into German, with a description of the medicinal action of cinchona bark, which, according to Cullen, was due to its astringent properties. Hahnemann conducted a now famous self-experiment with cinchona bark on himself in which he observed the typical ma- larial symptoms of intermittent fever. It was this experience that led him to an exposition of the Law of Similars (Similarity Principle) and marked the beginning of systematically conducted homeopathic drug provings. While this first and most famous proving did not use a homeo- pathically prepared substance, Hahnemann explicitly recognized using homeopathically pre- pared medications in a homeopathic drug proving. The Similarity (Similia) Principle postulates that substances capable of causing symptoms in healthy subjects can be used as medicines to treat similar patterns of symptoms experienced by people when they are ill. Recognizing the symptoms of an individual subject and matching them with the symptom pattern from a homeopathic proving is considered to be a key element in the successful practice of homeopathy. Proving symptoms are defined as those changes of the mental, emotional or physical state of the subject that are likely to be caused by the administration of the remedy and are out of the or- dinary patterns of reaction for the subject as noted during the pre-proving observational period. Proving symptoms are generally temporary symptoms, lasting for several hours or days. In ho- meopathic drug provings, symptoms are recorded and may become components of the homeo- pathic symptom picture for that homeopathic medicinal product, which guide clinical application when they are verified in clinical practice and are included in homeopathic repertories. Hahnemann undertook over 100 homeopathic drug provings in order to understand »... the peculiar actions of medicines on the health of man ...« [§108 Organon, section 4, Hahnemann 1958]. He stressed the need for homeopathic drug provings on healthy volunteers using ho- meopathic preparations as the best method for achieving an accurate homeopathic symptom picture. In his »Organon of the Art of Healing« Hahnemann provided scientific directions on how to conduct a homeopathic drug proving [§§105–146, Hahnemann 1958]. Clinical research has changed since the time of Hahnemann. Homeopathic medicinal prod- ucts are classified as drugs in the United States and Europe, and these clinical studies follow the D. S. Riley, Materia Medica of New and Old Homeopathic Medicinces, DOI 10.1007/978-3-642-25292-1_1, © Springer-Verlag Berlin Heidelberg 2012 2 Chapter 1 · Homeopathic Drug Provings – An Introduction to General Methodological Considerations Good Clinical Practice Guidelines (GCP) including Institutional Review Board (IRB) approval. 1 They are similar to, but not identical to, phase-I trials as defined by the FDA. Homeopathic drug provings lack the toxicological risks that in phase-I trials are determined by conventional phar- macokinetics. In a homeopathic drug proving a homeopathically prepared substance is administered to healthy volunteers in order to produce the symptoms specific to that substance. The goal is to provoke temporary symptoms or an »artificial illness« associated with the homeopathic medica- tion. These symptoms are then arranged to form a symptom pattern or remedy picture, which is specific to that particular homeopathic substance and provides the basis for a better under- standing of the possible effects of that homeopathic remedy in patients. The collection of homeopathic drug provings reported in this book were conducted between 1993 and 2001 and generally lasted between 6 and 9 weeks per subject. The medications used in these homeopathic drug provings were most commonly prepared as globules in a 12C po- tency and were administered three times daily until the subjects developed symptoms. No medication was taken after a subject began to experience symptoms. Various scientific research methods were utilized with the primary goal of reducing bias. For example, all of the medications used in these provings were either verum or placebo accord- ing to a computer-generated randomized code known only to the manufacturer of the study medication until the blind was broken at the end of the homeopathic drug proving. Placebo controls were used in order to ensure that neither the subjects nor the investigator knew wheth- er a subject was receiving verum or placebo while the trial was ongoing. The remedy was com- monly, but not always, administered on two separate occasions. In some of these provings the first administration of the remedy was a placebo run-in period and in others the subjects were randomized into parallel groups to receive either verum or placebo. All subjects who participated in these homeopathic drug provings were recruited via advertise- ments, selected using inclusion and exclusion criteria, educated about homeopathic drug provings, and signed an informed consent approved by an Institutional Review Board. While there was some variation in the wording, a sample of the inclusion and exclusion criteria is given below: Inclusion Criteria 4 Age =18 years and <75 years 4 General state of good health 4 Continuation of the usual habits and patterns of daily living 4 Written informed consent and willingness to comply with the requirements of the study Exclusion Criteria 4 Any major life changes, e.g. moving, getting married or divorced etc. 4 Current or expected medical treatment or surgery during this homeopathic drug proving 4 Surgery within the past 4 weeks prior to enrollment into the homeopathic drug proving 4 Use of homeopathic medicines >30C or contraceptive pills in the month prior to enrollment into the homeopathic drug proving 4 Alcohol or drug abuse 4 Pregnancy or nursing (or anticipating pregnancy during this homeopathic drug proving) 4 Incompetence, or inability to understand the nature, meaning and consequences of the homeopathic drug proving or inadequate completion of the journal 4 Participation in another clinical trial at the same time or within the past 4 weeks. The central investigational tool of these homeopathic drug provings was the journal kept by each subject